Actively Recruiting
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Led by Mayo Clinic · Updated on 2026-02-23
2000
Participants Needed
3
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying next generation sequencing (NGS) to detect early signs of pre-myeloid cancers and bone marrow failure syndromes. This approach examines genes linked to cancer to find genetic markers that may identify patients at risk before full cancer develops. The study aims to diagnose and better understand these precursor conditions, their progression risks, and to explore possible therapeutic directions using genomics and functional studies. Participants may undergo various procedures including blood sample collection, bone marrow biopsy, skin punch biopsy, hair follicle collection, buccal swab, and saliva collection for NGS analysis. Additional clinical assessments and genetic counseling may be provided. The study also includes ancillary evaluations like quality-of-life assessments and electronic health record reviews to support research objectives. During the study, participants will have samples collected and may receive clinical evaluation and counseling. Researchers will monitor outcomes such as the occurrence of cytopenias, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) for up to five years. The study involves careful analysis of genetic and epigenetic data, as well as assessments of frailty compared to standard care. The total follow-up period can extend up to several years to observe disease progression and related outcomes.
CONDITIONS
Brief Title
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with idiopathic cytopenias of unclear significance (ICUS)
- Patients with clonal hematopoiesis of indeterminate significance (CHIP), including VEXAS syndrome
- Patients with clonal cytopenias of undetermined significance (CCUS)
- Patients with marrow failure syndromes linked to myeloid malignancy risk, such as telomere dysfunction or chromosomal breakage disorders
- Patients with germline inherited syndromes increasing risk for malignancy, including GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6
- Patients with low risk myelodysplastic syndrome (idiopathic dysplasia of unclear significance)
- Family members of patients with any of the above conditions
- Patients at high risk or suspected of developing any of the above conditions
You will not qualify if you...
- Patients under 18 years of age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Up to 5 years
Participants undergo biospecimen collections including blood samples, bone marrow biopsy, skin punch biopsy, hair follicle collection, buccal swab, and saliva collection for genetic analysis. They may also have clinical assessments and receive genetic counseling as part of ongoing observation.
Visits scheduled as needed for sample collection and assessments
Trial Site Locations
Total: 3 locations
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
2
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
Actively Recruiting
3
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
D
Dani Rud
C
Clinical Trials Referral Office
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here